HLS Therapeutics, Inc. (HLS.TO)
4.09
-0.11
(-2.62%)
CAD |
TSX |
Oct 09, 16:00
HLS Therapeutics Gross Profit Margin (Quarterly) : 42.90% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 42.90% |
| March 31, 2026 | 36.12% |
| December 31, 2025 | 46.65% |
| September 30, 2025 | 40.43% |
| June 30, 2025 | 43.63% |
| March 31, 2025 | 38.54% |
| December 31, 2024 | 47.76% |
| September 30, 2024 | 45.03% |
| June 30, 2024 | 43.80% |
| March 31, 2024 | 38.32% |
| December 31, 2023 | 39.61% |
| September 30, 2023 | 37.16% |
| June 30, 2023 | 38.22% |
| March 31, 2023 | 33.84% |
| December 31, 2022 | 34.87% |
| September 30, 2022 | 35.11% |
| June 30, 2022 | 37.92% |
| March 31, 2022 | 35.83% |
| December 31, 2021 | 41.57% |
| September 30, 2021 | 43.21% |
| June 30, 2021 | 43.95% |
| March 31, 2021 | 43.13% |
| December 31, 2020 | 34.34% |
| September 30, 2020 | 41.05% |
| June 30, 2020 | 29.64% |
| Date | Value |
|---|---|
| March 31, 2020 | 32.48% |
| December 31, 2019 | 38.02% |
| September 30, 2019 | 35.40% |
| June 30, 2019 | 36.69% |
| March 31, 2019 | 35.43% |
| December 31, 2018 | 48.18% |
| September 30, 2018 | 41.34% |
| June 30, 2018 | 46.83% |
| March 31, 2018 | 33.76% |
| September 30, 2017 | 46.62% |
| June 30, 2017 | 55.41% |
| March 31, 2017 | 46.27% |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 38.80% |
| September 30, 2014 | 34.27% |
| June 30, 2014 | 23.60% |
| March 31, 2014 | 29.85% |
| December 31, 2013 | 28.21% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Bausch Health Cos., Inc. | 65.04% |
| Cipher Pharmaceuticals, Inc. | 65.58% |
| BioSyent, Inc. | 65.02% |
| Revive Therapeutics Ltd. | -- |
| Knight Therapeutics, Inc. | 38.94% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -14.03% |
| Return on Assets | -6.21% |
| Return on Invested Capital | -7.76% |
| Profit Margin (Quarterly) | -6.95% |
| Operating Margin (Quarterly) | -7.88% |
| Return on Net Operating Assets | -7.04% |